• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Korean FDA approves STAAR Surgical's TICL

Article

Monrovia, CA—STAAR Surgical Co. said it has received approval from the Korean Food and Drug Administration (KFDA) to market the STAAR Visian Toric lens (TICL) in South Korea.

Monrovia, CA-STAAR Surgical Co. said it has received approval from the Korean Food and Drug Administration (KFDA) to market the STAAR Visian Toric lens (TICL) in South Korea.

The TICL is the first myopic ICL to receive KFDA approval, according to the company.

"This product will allow us to serve a broader population and further build our presence in our second-largest market for the myopic ICL," said David Bailey, president and chief executive officer of STAAR Surgical. The new market should provide a "meaningful increase" to the company's refractive business, he added.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.